Adrian Egli1, Aviad Levin2, Deanna M Santer2, Michael Joyce2, Daire O'Shea2, Brad S Thomas2, Luiz F Lisboa2, Khaled Barakat3, Rakesh Bhat2, Karl P Fischer2, Michael Houghton2, D Lorne Tyrrell2, Deepali Kumar4, Atul Humar4. 1. Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada Infection Biology, Department Biomedicine, University of Basel, Switzerland. 2. Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada. 3. Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada Department of Engineering Mathematics and Physics, Fayoum University, Egypt; 4. Department of Medicine and Multi-organ Transplant Program, University Health Network, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Feedback mechanisms between interferons α and λ (IFNs) may be affected by single nucleotide polymorphisms (SNP) in interleukin 28B (IL-28B; IFN-λ3) promoter region and may influence cytomegalovirus (CMV) replication. METHODS: We associated IL-28B SNPs with the risk of CMV replication after transplantation. Next, we examined the effect of IL-28B genotypes on IL-28B, and IFN-stimulated gene (ISG) expression, and CMV replication in human foreskin fibroblast (HFF) and peripheral blood mononuclear cells (PBMCs). RESULTS: Transplant recipients with an IL-28B SNP (rs8099917) had significantly less CMV replication (P = .036). Both HFF-cells and PBMCs with a SNP showed lower IL-28B expression during infection with CMV, but higher "antiviral" ISG expression (eg, OAS1). Fibroblasts with a SNP had a 3-log reduction of CMV replication at day 4 (P = .004). IL-28B pretreatment induced ISG expression in noninfected fibroblasts, but a relative decrease of ISG expression could be observed in CMV-infected fibroblasts. The inhibitory effects of IL-28B could be abolished by siRNA or antagonistic peptides against the IL-28 receptor. In fibroblasts, inhibition of IL-28 signaling resulted in an increase of ISG expression and 3-log reduction of CMV-replication (P = .01). CONCLUSIONS: We postulate that IL-28B may act as a key regulator of ISG expression during primary CMV infection. IL-28B SNPs may be associated with higher antiviral ISG expression, which results in better replication control.
BACKGROUND: Feedback mechanisms between interferons α and λ (IFNs) may be affected by single nucleotide polymorphisms (SNP) in interleukin 28B (IL-28B; IFN-λ3) promoter region and may influence cytomegalovirus (CMV) replication. METHODS: We associated IL-28B SNPs with the risk of CMV replication after transplantation. Next, we examined the effect of IL-28B genotypes on IL-28B, and IFN-stimulated gene (ISG) expression, and CMV replication in human foreskin fibroblast (HFF) and peripheral blood mononuclear cells (PBMCs). RESULTS: Transplant recipients with an IL-28B SNP (rs8099917) had significantly less CMV replication (P = .036). Both HFF-cells and PBMCs with a SNP showed lower IL-28B expression during infection with CMV, but higher "antiviral" ISG expression (eg, OAS1). Fibroblasts with a SNP had a 3-log reduction of CMV replication at day 4 (P = .004). IL-28B pretreatment induced ISG expression in noninfected fibroblasts, but a relative decrease of ISG expression could be observed in CMV-infected fibroblasts. The inhibitory effects of IL-28B could be abolished by siRNA or antagonistic peptides against the IL-28 receptor. In fibroblasts, inhibition of IL-28 signaling resulted in an increase of ISG expression and 3-log reduction of CMV-replication (P = .01). CONCLUSIONS: We postulate that IL-28B may act as a key regulator of ISG expression during primary CMV infection. IL-28B SNPs may be associated with higher antiviral ISG expression, which results in better replication control.
Authors: Helen M Lazear; Brian P Daniels; Amelia K Pinto; Albert C Huang; Sarah C Vick; Sean E Doyle; Michael Gale; Robyn S Klein; Michael S Diamond Journal: Sci Transl Med Date: 2015-04-22 Impact factor: 17.956
Authors: Adewonuola A Alase; Yasser M El-Sherbiny; Edward M Vital; Desmond J Tobin; Neil A Turner; Miriam Wittmann Journal: J Invest Dermatol Date: 2015-08-19 Impact factor: 8.551